EPHB3
MOLECULAR TARGETEPH receptor B3
EPHB3 (EPH receptor B3) is targeted by 16 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting EPHB3
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | foretinib | 4.34 | 76 |
| 2 | ponatinib | 4.26 | 70 |
| 3 | nilotinib | 4.17 | 64 |
| 4 | bosutinib | 4.08 | 58 |
| 5 | doramapimod | 4.06 | 57 |
| 6 | tae 684 | 3.43 | 30 |
| 7 | linifanib | 3.33 | 27 |
| 8 | mln 8054 | 3.33 | 27 |
| 9 | dasatinib anhydrous | 3.09 | 21 |
| 10 | danusertib | 2.94 | 18 |
| 11 | milciclib | 2.77 | 15 |
| 12 | tivozanib | 2.64 | 13 |
| 13 | golvatinib | 2.20 | 8 |
| 14 | asp 3026 | 2.08 | 7 |
| 15 | bafetinib | 1.95 | 6 |
| 16 | Dasatinib | 0.69 | 1 |
About EPHB3 as a Drug Target
EPHB3 (EPH receptor B3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 16 compounds with documented EPHB3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
EPHB3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.